letter
Letter
HLA-DRB1*0901 lowers anti-cyclic citrullinated peptide antibody levels in Japanese patients with rheumatoid arthritis
1 The University of Tokyo, Japan;
2 Institute of Physical and Chemical Research (RIKEN), Japan;
3 Institute of Medical Science, the University of Tokyo, Japan
Correspondence to: Yukinori Okada, Department of Allergy and Rheumatology, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan; yokada-tky{at}umin.ac.jp
Accepted 4 October 2009
Anti-cyclic citrullinated peptide (anti-CCP) antibody is a highly specific biomarker for Rheumatoid Arthritis (RA), and recognized as a predictor of development of RA.[1,2] It had been demonstrated that some HLA-DRB1 alleles, such as shared epitope (SE) alleles, significantly contribute to the positivity of anti-CCP antibody and the susceptibility of anti-CCP antibody-positive RA.[3,4] However, the quantitative effect of HLA-DRB1 alleles on anti-CCP antibody levels in RA patients is controversial.[3,5,6] Therefore, we carried out a large-scale study to study the quantitative effects of HLA-DRB1 alleles on anti-CCP antibody levels in Japanese patients with RA.
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
